Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Treasury Shares: 2022-2024

Historic Treasury Shares for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $4.5 million.

  • Taysha Gene Therapies' Treasury Shares rose 37.85% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 37.85%. This contributed to the annual value of $4.5 million for FY2024, which is 1112.97% up from last year.
  • As of FY2024, Taysha Gene Therapies' Treasury Shares stood at $4.5 million, which was up 1,112.97% from $375,044 recorded in FY2023.
  • Taysha Gene Therapies' 5-year Treasury Shares high stood at $4.5 million for FY2024, and its period low was $375,044 during FY2023.
  • Over the past 3 years, Taysha Gene Therapies' median Treasury Shares value was $1.3 million (recorded in 2022), while the average stood at $2.1 million.
  • Its Treasury Shares has fluctuated over the past 5 years, first crashed by 70.18% in 2023, then spiked by 1,112.97% in 2024.
  • Over the past 3 years, Taysha Gene Therapies' Treasury Shares (Yearly) stood at $1.3 million in 2022, then plummeted by 70.18% to $375,044 in 2023, then soared by 1,112.97% to $4.5 million in 2024.